Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 19/20 | 0.55 |
| ▸ | MMP3 | P08254 | 9/20 | 0.55 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | MMP7 | P09237 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8053893 | 0.91 | MMP2 (0.54) | MMP2MMP3MMP1MMP9MMP7 | |
| SCHEMBL8057878 | 0.91 | MMP2 (0.54) | MMP2MMP3MMP1MMP9MMP7 | |
| SCHEMBL8053746 | 0.91 | MMP2 (0.54) | MMP2MMP3MMP1MMP9MMP7 | |
| SCHEMBL8060170 | 0.91 | MMP2 (0.54) | MMP2MMP3MMP1MMP9MMP7 | |
| SCHEMBL8054967 | 0.79 | MMP2 (0.42) | MMP2MMP3MMP1MMP7 | |
| SCHEMBL8055024 | 0.79 | CTSK (0.44) | MMP2MMP3MMP1 | |
| SCHEMBL3842681 | 0.78 | TAAR1 (0.48) | MMP3MMP1 | |
| SCHEMBL7373357 | 0.75 | MMP2 (0.57) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL7319632 | 0.74 | GRIK1 (0.64) | MMP2MMP3 | |
| SCHEMBL9574068 | 0.73 | MMP2 (0.57) | MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0809491-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF DISEASES MEDIATED BY TNF-ALPHA | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996025156-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF DISEASES MEDIATED BY TGF-ALPHA | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-08-22 | — | — | WO | disclosed |